文献速递神经肿瘤

MRI与FET PET预测复发胶质瘤患者对洛莫司汀为基础化疗的应答

Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
PubMed 文献 · Neuro Oncol · 2023-01-01

本研究回顾性纳入36例复发WHO中枢神经系统3级或4级胶质瘤成人患者,评估FET PET与MRI在洛莫司汀为基础化疗早期应答评估中的作用。结果显示TBR、MTV相对变化及RANO标准可预测显著更长的PFS和OS,随访时出现新远隔热点预测更差结局,多变量分析显示其预测无应答效力最强(P<.001;HR 8.578)。结论提示FET PET在治疗早期可为RANO标准提供补充信息。

要点

  • 复发胶质瘤洛莫司汀化疗早期,TBR、MTV相对变化及RANO标准可预测显著更长PFS和OS。
  • 随访FET PET出现新远隔热点(平均TBR>1.6,n≥1)预测更短PFS(P=.005)和OS(P<.001)。
  • 多变量分析显示新远隔热点预测无应答效力最强(P<.001;HR 8.578)。

核心结论

  • 数据提示FET PET在洛莫司汀为基础化疗开始后早期可为RANO标准提供补充信息用于应答评估。

研究设计与样本

  • 回顾性识别36例复发WHO中枢神经系统3级或4级胶质瘤成人患者(胶质母细胞瘤占69%),复发中位次数1次(范围1-3)。
  • 除MRI外,在基线和化疗开始后早期(不晚于两个周期)进行系列FET PET扫描。
  • 从所有FET PET扫描中获取肿瘤-脑比值(TBR)、代谢性肿瘤体积(MTV)、随访时出现平均TBR>1.6的新远隔热点以及动态参数达峰时间。
  • 使用ROC分析定义PET参数阈值以预测PFS≥6个月和OS≥12个月。
  • MRI应答评估基于RANO标准,随后使用单变量和多变量生存估计评估FET PET参数和RANO标准的预测价值。

主要发现

  • 治疗开始后中位随访时间为11个月(范围3-71个月)。
  • TBR、MTV相对变化和RANO标准预测显著更长的PFS(所有P≤.002)和OS(所有P≤.045)。
  • 随访时出现新远隔热点(n≥1)预测更差结局,PFS显著更短(P=.005)和OS显著更短(P<.001)。
  • 达峰时间变化未预测显著更长的生存。
  • 多变量生存分析显示随访FET PET新远隔热点预测无应答效力最强(P<.001;HR 8.578)。

关键数值与推荐

  • PET参数阈值通过ROC分析定义以预测PFS≥6个月和OS≥12个月。
  • 新远隔热点定义为随访时出现平均TBR>1.6。
  • MRI应答评估基于RANO标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy. METHODS: Thirty-six adult patients with WHO CNS grade 3 or 4 gliomas (glioblastoma, 69%) at recurrence (median number of recurrences, 1; range, 1-3) were retrospectively identified. Besides MRI, serial FET PET scans were performed at baseline and early after chemotherapy initiation (not later than two cycles). Tumor-to-brain ratios (TBR), metabolic tumor volumes (MTV), the occurrence of new distant hotspots with a mean TBR >1.6 at follow-up, and the dynamic parameter time-to-peak were derived from all FET PET scans. PET parameter thresholds were defined using ROC analyses to predict PFS of ≥6 months and OS of ≥12 months. MRI response assessment was based on RANO criteria. The predictive values of FET PET parameters and RANO criteria were subsequently evaluated using univariate and multivariate survival estimates. RESULTS: After treatment initiation, the median follow-up time was 11 months (range, 3-71 months). Relative changes of TBR, MTV, and RANO criteria predicted a significantly longer PFS (all P ≤ .002) and OS (all P ≤ .045). At follow-up, the occurrence of new distant hotspots (n ≥ 1) predicted a worse outcome, with significantly shorter PFS (P = .005) and OS (P < .001). Time-to-peak changes did not predict a significantly longer survival. Multivariate survival analyses revealed that new distant hotspots at follow-up FET PET were most potent in predicting non-response (P < .001; HR, 8.578). CONCLUSIONS: Data suggest that FET PET provides complementary information to RANO criteria for response evaluation of lomustine-based chemotherapy early after treatment initiation.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wollring MM, Werner JM, Bauer EK, et al. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro Oncol. 2023. PMID: 36215231. doi:10.1093/neuonc/noac229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。